ClinicalTrials.gg
RecruitingNCT06551662PICCOLETO VUpdated Dec 4, 2025

DCB vs. DES in Bifurcation Coronary Lesions

An interventional study of Paclitaxel drug-coated balloons and Sirolimus drug-coated balloons in Coronary Artery Disease and DCB, sponsored by Fondazione Ricerca e Innovazione Cardiovascolare ETS. Recruiting at 17 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Fondazione Ricerca e Innovazione Cardiovascolare ETS · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
321
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies in Coronary Artery Disease with a site in Poland — 33 open to participants now, 47 under way, 4 of them phase 3. Coronary Artery Disease · Poland.

Planned enrollment
62nd of 114
321 · median 348
Started
2025
with 10 others
No phase
64 of 154
17 open now
Primary completion
2026-02
later than 12 of 46 live
Registered
137th of 154
by date

Among the 154 studies in Coronary Artery Disease with a site in Poland, this one is the 62nd largest by planned enrollment of the 114 interventional ones that give a count, is one of 11 that started in 2025, is one of 64 with no phase, reaches primary completion later than 12 of the 46 other live ones, and was the 137th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

33 of the 154 studies in Coronary Artery Disease with a site in Poland are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Coronary Artery Disease with a site in Poland, or all of them as a file.
02

Study summary

This is an investigator-driven prospective, multicentric, international, randomized clinical study, in an open-label randomized fashion, where patients with bifurcation coronary artery disease (Medina: 111,101,011,001) in vessels with diameter >2.0 (visual estimation) and with a clinical indication to PCI, will be enrolled. After successful predilatation (with any tool deemed useful), patients will be randomized 1:1:1 to SCB, PCB or standard treatment with DES for bifurcation native vessel disease. All patients with a clinical indication for PCI, both stable coronary artery disease and acute coronary syndrome, will be enrolled.

Before participating all the candidates will be clearly informed about the study, including the possible risks and benefits, and will be asked to provide a written informed consent. Subjects will be instructed that may not meet the general criteria for inclusion or the angiographic criteria, or that may have at least one exclusion criteria, and then be excluded from the study (screening failure), even after informed consent is obtained.

Consecutive patients who meet at least one of the inclusion criteria and none of the exclusion criteria, will participate to the study. After randomization, the procedure will consist in standard coronary angioplasty following international guidelines/consensus documents and as per local practice. If the patient has been randomized to SCB or PCB, it is mandatory to adequately prepare the lesion.

03

Conditions studied

  • Coronary Artery Disease
  • DCB

Keywords

  • Coronary artery disease
  • Bifurcation coronary lesions
  • Drug-coated balloons
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be age ≥18 years.
  • Subject has silent ischemia, or stable/unstable angina, or acute MI older than 1-week from the onset of chest pain to admission.
  • Subject understands the trial design and treatment procedures and provides written informal consent before entering the trial
  • Subject is willing to comply with all protocol-required follow-up evaluations.
  • Target lesion must be native non-LM bifurcation lesion
  • Target lesion must be a bifurcation lesion on coronary angiography (defined as Medina 0,1,1, Medina 1,0,1, Medina 1,1,1 or Medina 0,0,1 coronary bifurcation lesions) and is eligible for percutaneous coronary intervention (PCI).
  • Target lesion reference vessel diameter (both main vessel and side branch)

    • 2.0 mm by visual estimation.
  • Target lesion must have visually estimated stenosis ≥50%.
  • Target lesion length of side branch must be \<25 mm by visual estimation.

Exclusion criteria

Exclusion Criteria:

  • Patient with STEMI (within 3 days from the onset of chest pain to coronarography).
  • Patient has known allergy to the study balloon/stent system.
  • Patient has any other serious medical illness that may reduce to less than 12 months.
  • Patient is pregnant or nursing.
  • Patient is participating in another clinical trial that has not reached its primary endpoint within 24 months after the index procedure.
  • Patient has a planned procedure that may cause non-compliance with the protocol or confound data interpretation.
  • In-stent restenosis lesion.
  • Chronic total occlusion (CTO) lesion in either main vessel or side branch.
  • \<30%;
  • Visible and untreatable thrombus at lesion site;
  • Target lesion/vessel with any of the following characteristics:

    • Severe and/or >270° calcification of the target vessel, also proximal to the lesion (intravascular imaging);
    • Bifurcation lesion where stent strategy is anticipated;
    • Left main stem stenosis >50%;
    • Target lesion is in the left main stem;
    • Lesions length >50 mm (main vessel)
    • Lesions length >25 mm (side branch)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
321 participants (estimated)

Study arms

  • Experimental
    Device: Paclitaxel drug-coated-balloons

    Device: Paclitaxel drug-coated balloons

  • Experimental
    Device: Sirolimus drug-coated-balloons

    Device: Sirolimus drug-coated balloons

  • Active comparator
    Device: new generation drug-eluting-stents

    Device: New generation drug-eluting stent

Interventions

  • DevicePaclitaxel drug-coated balloons

    Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent

  • DeviceSirolimus drug-coated balloons

    Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent

  • DeviceNew generation drug-eluting stent

    Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent

06

What researchers measure

Primary outcomes

  1. 6-9 Month CT-FFR or Invasive FFR in Bifurcation Lesions

    6-9-month CT-scan FFR (core lab) * 6-9-month Main vessel CT-FFR * 6-9-month Side branch CT-FFR or If invasive coronary angiography indicated at 6-9 months: * invasive FFR of Main vessel * invasive FFR of Side branch

    Time frame: 6-9-month

  2. 6-9-Month CT-FFR or Invasive FFR: % Max Stenosis (Main + Side Branch)

    6-9-month CT-scan FFR (core lab): * Main vessel % maximum stenosis * Side branch % maximum stenosis or If invasive coronary angiography indicated at 6-9 months: * Main vessel % maximum stenosis * Side branch % maximum stenosis

    Time frame: 6-9-month

Secondary outcomes

  1. MACE

    The MACE was defined as a composite of total mortality, TVR, and spontaneous TV-MI.

    Time frame: 24 +/- 1 months

  2. Cardiac death

    Cardiac death rates at 24+/- 1 months follow-up

    Time frame: 24+/- 1 months

  3. All-cause death

    All-cause death rates at 24+/- 1 months follow-up

    Time frame: 24+/- 1 months

  4. Q-wave MI

    Q-wave MI rates at 24+/- 1 months follow-up

    Time frame: 24+/- 1 months

  5. Any MI

    Any MI rates at 24+/- 1 months follow-up

    Time frame: 24+/- 1 months

  6. TLR

    TLR rates at 24+/- 1 months follow-up

    Time frame: 24+/- 1 months

  7. TVR

    TVR rates at 24+/- 1 months follow-up

    Time frame: 24+/- 1 months

  8. Vessel thrombosis

    Vessel thrombosis rates at 24+/- 1 months follow-up

    Time frame: 24+/- 1 months

  9. Bleedings following BARC classification

    Bleedings following BARC classification at 24+/- 1 months follow-up

    Time frame: 24+/- 1 months

07

Study locations

2 of 17 sites recruiting
  • Fondazione Ricerca e Innovazione Cardiovascolare
    Milan, Italy
    Not yet recruiting
    • Bernardo Cortese · Contact
    • Bernardo Cortese · Principal investigator
  • First Department of Cardiology, Medical University of Gdansk, Gdansk, Poland
    Gdansk, Poland
    Not yet recruiting
    • Maksymilian Mielczarek, Prof. · Contactmax.mielczarek@gmail.com
    • Miłosz Jaguszewski, Prof. · Sub investigator
    • Maksymilian Mielczarek, MD, PhD · Principal investigator
    • Dariusz Cieświerz, MD, PhD · Sub investigator
  • Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
    Katowice, 40-635, Poland
    Not yet recruiting
    • Wojciech Wańha, MD, PhD · Contactwojciech.wanha@gmail.com · 0048504827636
    • Wojciech Wańha, PhD · Principal investigator
    • Wojciech Wojakowski, Prof. · Principal investigator
    • Grzegorz Smolka, Prof. · Principal investigator
  • Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland
    Krakow, Poland
    Not yet recruiting
    • Jacek Legutko · Contactjacek.legutko@uj.edu.pl
    • Jacek Legutko, Prof. · Principal investigator
    • Paweł Kleczyński, Prof. · Principal investigator
  • Second Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland
    Krakow, Poland
    Not yet recruiting
    • Stanisław Bartuś, Prof. · Contactmbbartus@gmail.com · 12 400 22 50
    • Stanisław Bartuś, Prof. · Principal investigator
  • Department of Cardiology, Copper Health Centre (MCZ)
    Lubin, Poland
    Not yet recruiting
  • Clinical Department of Interventional Cardiology, Medical University of Lublin
    Lublin, Poland
    Not yet recruiting
  • Department of Cardiology, Poznan University of Medical Sciences
    Poznan, Poland
    Not yet recruiting
    • Sylwia Iwańczyk, MD, PhD · Contactsyl.iwanczyk@gmail.com
    • Sylwia Iwańczyk, MD, PhD · Principal investigator
    • Maciej Lesiak, Prof. · Sub investigator
    • Miłosz Dziarmaga, MD, PhD · Sub investigator
  • Department of Cardiology, The Ministry of Internal Affairs and Administration Hospital, Rzeszow
    Rzeszów, Poland
    Not yet recruiting
  • Department of Cardiology and Internal Diseases, Military Institute of Medicine
    Warsaw, Poland
    Not yet recruiting
    • Piotr Kwiatkowski, MD · Contact
  • Department of Invasive Cardiology, Centre of Postgraduate Medical Education, Central Clinical Hospital of the Ministry of Interior and Administration
    Warsaw, Poland
    Not yet recruiting
    • Robert Gil, Prof. · Contactscorpirg@gmail.com · (22) 508 11 00
    • Robert Gil, Prof. · Principal investigator
    • Tomasz Pawłowski, Prof. · Principal investigator
  • Department of Cardiology
    Wałbrzych, Poland
    Not yet recruiting
    • Jacek Bezubka · Contact
  • Centre for Heart Disease, University Hospital Wroclaw Department of Heart Disease, Wroclaw Medical University
    Wroclaw, Poland
    Not yet recruiting
    • Wiktor Kuliczkowski, Prof. · Contactwkuliczkowski@wp.pl
    • Wiktor Kuliczkowski, Prof. · Principal investigator
  • Third Department of Cardiology, Medical University of Katowice
    Zabrze, Poland
    Not yet recruiting
    • Mariusz Gąsior, Prof. · Contactm.gasior@op.pl · 32 373 36 00
    • Mariusz Gąsior, Prof. · Principal investigator
  • Heart Institute, Cluj-Napoca
    Cluj-Napoca, Romania
    Recruiting
  • Sibiu County Emergency Clinical Hospital
    Sibiu, Romania
    Recruiting
  • Tan Tock Seng Hospital
    Singapore, Singapore
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Feb 2026, 6 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 6 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Aug 13, 2024
StartActual
Aug 1, 2025
Primary completionEst.
Feb 1, 2026
CompletionEst.
Feb 1, 2028
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06551662
Lead sponsor
Fondazione Ricerca e Innovazione Cardiovascolare ETS
Responsible party
Sponsor
First posted
Aug 13, 2024
Start date
Aug 1, 2025
Primary completion
Feb 1, 2026 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Dec 4, 2025

Study contacts

Bernardo Cortese
Contact
bcortese@gmail.com
504827636
Wojciech Wańha
Contact
wojciech.wanha@gmail.com
504827636

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion